Dr. Bradley on the Background of the RTOG 0617 Study

Jeffrey D. Bradley, MD
Published: Tuesday, Jun 18, 2013

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses the background of the phase III RTOG 0617 study.

In the phase III randomized trial, patients with stage III non-small cell lung cancer were randomized to high-dose (74 Gy) or standard-dose (60 Gy) chemoradiotherapy with or without cetuximab. Patients were divided into four arms in a 2x2 factorial design.

The second randomization in this trial was for patients to be given cetuximab during and after radiation therapy. At the 2013 American Society of Clinical Oncology Meeting, Bradley presented on the first randomization -- the radiation dose question.

<<< View more from the 2013 ASCO Annual Meeting

SELECTED
LANGUAGE
Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses the background of the phase III RTOG 0617 study.

In the phase III randomized trial, patients with stage III non-small cell lung cancer were randomized to high-dose (74 Gy) or standard-dose (60 Gy) chemoradiotherapy with or without cetuximab. Patients were divided into four arms in a 2x2 factorial design.

The second randomization in this trial was for patients to be given cetuximab during and after radiation therapy. At the 2013 American Society of Clinical Oncology Meeting, Bradley presented on the first randomization -- the radiation dose question.

<<< View more from the 2013 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x